Eisai Co Ltd
TSE:4523
| US |
|
Fubotv Inc
NYSE:FUBO
|
Media
|
| US |
|
Bank of America Corp
NYSE:BAC
|
Banking
|
| US |
|
Palantir Technologies Inc
NYSE:PLTR
|
Technology
|
| US |
C
|
C3.ai Inc
NYSE:AI
|
Technology
|
| US |
|
Uber Technologies Inc
NYSE:UBER
|
Road & Rail
|
| CN |
|
NIO Inc
NYSE:NIO
|
Automobiles
|
| US |
|
Fluor Corp
NYSE:FLR
|
Construction
|
| US |
|
Jacobs Engineering Group Inc
NYSE:J
|
Professional Services
|
| US |
|
TopBuild Corp
NYSE:BLD
|
Consumer products
|
| US |
|
Abbott Laboratories
NYSE:ABT
|
Health Care
|
| US |
|
Chevron Corp
NYSE:CVX
|
Energy
|
| US |
|
Occidental Petroleum Corp
NYSE:OXY
|
Energy
|
| US |
|
Matrix Service Co
NASDAQ:MTRX
|
Construction
|
| US |
|
Automatic Data Processing Inc
NASDAQ:ADP
|
Technology
|
| US |
|
Qualcomm Inc
NASDAQ:QCOM
|
Semiconductors
|
| US |
|
Ambarella Inc
NASDAQ:AMBA
|
Semiconductors
|
If you don’t study any companies, you have the same success buying stocks as you do in a poker game if you bet without looking at your cards.
Utilize notes to systematically review your investment decisions. By reflecting on past outcomes, you can discern effective strategies and identify those that underperformed. This continuous feedback loop enables you to adapt and refine your approach, optimizing for future success.
Each note serves as a learning point, offering insights into your decision-making processes. Over time, you'll accumulate a personalized database of knowledge, enhancing your ability to make informed decisions quickly and effectively.
With a comprehensive record of your investment history at your fingertips, you can compare current opportunities against past experiences. This not only bolsters your confidence but also ensures that each decision is grounded in a well-documented rationale.
Do you really want to delete this note?
This action cannot be undone.
| 52 Week Range |
4 619
7 776
|
| Price Target |
|
We'll email you a reminder when the closing price reaches JPY.
Choose the stock you wish to monitor with a price alert.
|
|
Fubotv Inc
NYSE:FUBO
|
US |
|
|
Bank of America Corp
NYSE:BAC
|
US |
|
|
Palantir Technologies Inc
NYSE:PLTR
|
US |
|
C
|
C3.ai Inc
NYSE:AI
|
US |
|
|
Uber Technologies Inc
NYSE:UBER
|
US |
|
|
NIO Inc
NYSE:NIO
|
CN |
|
|
Fluor Corp
NYSE:FLR
|
US |
|
|
Jacobs Engineering Group Inc
NYSE:J
|
US |
|
|
TopBuild Corp
NYSE:BLD
|
US |
|
|
Abbott Laboratories
NYSE:ABT
|
US |
|
|
Chevron Corp
NYSE:CVX
|
US |
|
|
Occidental Petroleum Corp
NYSE:OXY
|
US |
|
|
Matrix Service Co
NASDAQ:MTRX
|
US |
|
|
Automatic Data Processing Inc
NASDAQ:ADP
|
US |
|
|
Qualcomm Inc
NASDAQ:QCOM
|
US |
|
|
Ambarella Inc
NASDAQ:AMBA
|
US |
This alert will be permanently deleted.
Eisai Co Ltd
Eisai Co Ltd
Accounts Receivables
Eisai Co Ltd
Accounts Receivables Peer Comparison
Competitors Analysis
Latest Figures & CAGR of Competitors
| Company | Accounts Receivables | CAGR 3Y | CAGR 5Y | CAGR 10Y | ||
|---|---|---|---|---|---|---|
|
|
Eisai Co Ltd
TSE:4523
|
Accounts Receivables
¥205.4B
|
CAGR 3-Years
-5%
|
CAGR 5-Years
4%
|
CAGR 10-Years
1%
|
|
|
Takeda Pharmaceutical Co Ltd
TSE:4502
|
Accounts Receivables
¥700.5B
|
CAGR 3-Years
-6%
|
CAGR 5-Years
-2%
|
CAGR 10-Years
4%
|
|
|
Daiichi Sankyo Co Ltd
TSE:4568
|
Accounts Receivables
¥531.8B
|
CAGR 3-Years
24%
|
CAGR 5-Years
9%
|
CAGR 10-Years
7%
|
|
|
Otsuka Holdings Co Ltd
TSE:4578
|
Accounts Receivables
¥470.4B
|
CAGR 3-Years
9%
|
CAGR 5-Years
6%
|
CAGR 10-Years
4%
|
|
|
Chugai Pharmaceutical Co Ltd
TSE:4519
|
Accounts Receivables
¥239.7B
|
CAGR 3-Years
-6%
|
CAGR 5-Years
4%
|
CAGR 10-Years
6%
|
|
|
Astellas Pharma Inc
TSE:4503
|
Accounts Receivables
¥587.7B
|
CAGR 3-Years
17%
|
CAGR 5-Years
10%
|
CAGR 10-Years
6%
|
|
Eisai Co Ltd
Glance View
Eisai Co., Ltd., founded in 1941 and headquartered in Tokyo, Japan, stands as a prominent global player in the pharmaceutical industry, dedicated to research and development in areas such as neurology and oncology. With a mission encapsulated in their philosophy of "human health care" (hhc), Eisai strives not only for profit but also for the well-being of patients, positioning itself as a company that deeply values purpose alongside its financial goals. Over the years, Eisai has gained recognition for its innovative products, particularly the Alzheimer's treatment, Aricept, which has generated a substantial portion of its revenue. Investors might find this focus on neurodegenerative diseases particularly compelling, given the aging global population and the increasing prevalence of conditions like Alzheimer's. Eisai's commitment to innovation is complemented by strategic partnerships and collaborations, including notable alliances with big biotech and pharmaceutical companies, enhancing its research capabilities and market reach. With a firm commitment to sustainability and environmental issues, the company not only focuses on profitability but also adheres to a long-term vision that resonates with contemporary investment ideals. As Eisai moves forward, its pipeline of products, including promising cancer therapies, offers investors a glimpse into its growth potential and the company's adaptability within a rapidly changing healthcare landscape. This combination of ethical responsibility, strategic growth, and market relevance positions Eisai as an intriguing prospect for investors searching for both stability and potential in the pharmaceutical sector.
See Also
What is Eisai Co Ltd's Accounts Receivables?
Accounts Receivables
205.4B
JPY
Based on the financial report for Jun 30, 2024, Eisai Co Ltd's Accounts Receivables amounts to 205.4B JPY.
What is Eisai Co Ltd's Accounts Receivables growth rate?
Accounts Receivables CAGR 10Y
1%
Over the last year, the Accounts Receivables growth was 9%. The average annual Accounts Receivables growth rates for Eisai Co Ltd have been -5% over the past three years , 4% over the past five years , and 1% over the past ten years .
You don't have any saved screeners yet
